Introduction: Compensatory eating disorder (CED) is a newly proposed 'other specified feeding and eating disorder' characterized by recurrent non-purging compensatory behaviors (e.g., compulsive exercise and/or food restriction), overvaluation of weight/shape, the absence of objective binge-eating episodes, and the absence of low weight or recent significant weight loss. This study compared individuals with CED to individuals with anorexia nervosa (AN), bulimia nervosa (BN), or binge-eating disorder (BED) on measures of psychiatric impairment, eating-disorder (ED) symptomatology, and comorbid internalizing disorders.
Method: Adults (N = 187) with CED, AN, BN, or BED completed measures of ED-related-psychiatric impairment and ED symptomatology. Structured clinical interviews were administered to assess ED and internalizing-disorder diagnoses.
Results: Linear regression models were fit to compare the CED group to full-threshold ED groups on psychiatric impairment, body dissatisfaction, cognitive restraint, negative attitudes towards obesity, and weight suppression. A chi-square difference test examined group differences on internalizing-disorder prevalence. Results indicated that the CED group had high levels of psychiatric impairment, yet psychiatric impairment was significantly lower in the CED group compared to other groups. The AN group had significantly lower body dissatisfaction than the CED group. Individuals with CED had similar cognitive restraint, negative attitudes towards obesity, internalizing psychopathology, and weight suppression compared to other ED groups.
Conclusion: Individuals with CED had substantial ED psychopathology and internalizing-disorder prevalence, comparable to individuals with full-threshold EDs. Individuals with CED had high levels of psychiatric impairment, but their impairment was lower than individuals with full-threshold EDs. Our results indicate that CED is a clinically significant disorder.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eatbeh.2023.101823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Borderline Personality Disorder and Loneliness: Broadening the Scope of Treatment for Social Rehabilitation.
Harv Rev Psychiatry
December 2024
From McLean Hospital (Mr. Mermin and Dr. Choi-Kain) Belmont, MA; Harvard College (Ms. Steigerwald); Harvard Medical School (Dr. Choi-Kain).
Borderline personality disorder (BPD) has been described as a condition of intolerance of aloneness. This characteristic drives distinguishing criteria, such as frantic efforts to avoid abandonment. Both BPD and loneliness are linked with elevated mortality risk and multiple negative health outcomes.
View Article and Find Full Text PDFPlural molecular and cellular mechanisms of pore domain encephalopathy.
Elife
January 2025
Department of Neurology, Baylor College of Medicine, Houston, United States.
variants in children with neurodevelopmental impairment are difficult to assess due to their heterogeneity and unclear pathogenic mechanisms. We describe a child with neonatal-onset epilepsy, developmental impairment of intermediate severity, and G256W heterozygosity. Analyzing prior KCNQ2 channel cryoelectron microscopy models revealed G256 as a node of an arch-shaped non-covalent bond network linking S5, the pore turret, and the ion path.
View Article and Find Full Text PDFAn Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
JAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
Intraventricular Hemorrhage and Survival, Multimorbidity, and Neurodevelopment.
JAMA Netw Open
January 2025
Population Policy and Practice, Great Ormond Street UCL Institute of Child Health, London, United Kingdom.
Importance: Intraventricular hemorrhage (IVH) has proven to be a challenging and enduring complication of prematurity. However, its association with neurodevelopment across the spectrum of IVH severity, independent of prematurity, and in the context of contemporary care remains uncertain.
Objective: To evaluate national trends in IVH diagnosis and the association with survival and neurodevelopmental outcomes at 2 years of age.
Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.
Mov Disord
January 2025
Department of Neurology and Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA.
Background: Cognitive impairment is common at all stages of Parkinson's disease (PD), but there is no consensus on which neuropsychological tests to use or how to interpret cognitive battery results. A cognitive summary score (CSS) combines the richness of a neuropsychological battery with the simplicity of a single score.
Objective: The objective of this study was to determine whether a CSS created using robust norming can detect early cognitive deficits in de novo, untreated PD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!